Shanghai Haohai Biological Technology Co Ltd banner

Shanghai Haohai Biological Technology Co Ltd
SSE:688366

Watchlist Manager
Shanghai Haohai Biological Technology Co Ltd Logo
Shanghai Haohai Biological Technology Co Ltd
SSE:688366
Watchlist
Price: 39.1 CNY -0.26% Market Closed
Market Cap: ¥9B

EV/EBITDA

21.9
Current
22%
Cheaper
vs 3-y average of 28

Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.

EV/EBITDA
21.9
=
Enterprise Value
¥6.6B
/
EBITDA
¥302.4m

Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.

EV/EBITDA
21.9
=
Enterprise Value
¥6.6B
/
EBITDA
¥302.4m

Valuation Scenarios

Shanghai Haohai Biological Technology Co Ltd is trading below its 3-year average

If EV/EBITDA returns to its 3-Year Average (28), the stock would be worth ¥50.04 (28% upside from current price).

Statistics
Positive Scenarios
4/4
Maximum Downside
No Downside Scenarios
Maximum Upside
+149%
Average Upside
75%
Scenario EV/EBITDA Value Implied Price Upside/Downside
Current Multiple 21.9 ¥39.1
0%
3-Year Average 28 ¥50.04
+28%
5-Year Average 54.6 ¥97.54
+149%
Industry Average 41.6 ¥74.31
+90%
Country Average 28.8 ¥51.52
+32%

Forward EV/EBITDA
Today’s price vs future ebitda

Today's Enterprise Value EBITDA Forward EV/EBITDA
¥6.6B
/
Jan 2026
¥302.4m
=
21.9
Current
¥6.6B
/
Dec 2026
¥734.4m
=
9
Forward
¥6.6B
/
Dec 2027
¥855.8m
=
7.7
Forward

Forward EV/EBITDA shows whether today’s EV/EBITDA still looks high or low once future ebitda are taken into account.

Peer Comparison

All Multiples
EV/EBITDA
P/E
All Countries
Close
Market Cap EV/EBITDA P/E
CN
Shanghai Haohai Biological Technology Co Ltd
SSE:688366
8.8B CNY 21.9 35.2
FR
Pharnext SCA
OTC:PNEXF
6T USD -194 446.1 -160 127.7
US
Abbvie Inc
NYSE:ABBV
368.4B USD 14.4 86.7
US
Amgen Inc
NASDAQ:AMGN
191.5B USD 14.3 24.6
US
Gilead Sciences Inc
NASDAQ:GILD
170.8B USD 12.5 19.9
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
112.1B USD 21.2 28.3
US
Epizyme Inc
F:EPE
94.1B EUR -581 -533.6
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
79.3B USD 13.1 17.7
NL
argenx SE
XBRU:ARGX
43.8B EUR 43 39.6
AU
CSL Ltd
ASX:CSL
66.1B AUD 10.9 32.4
US
Seagen Inc
F:SGT
39.3B EUR -66.6 -61.8
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
CN
Shanghai Haohai Biological Technology Co Ltd
SSE:688366
Average EV/EBITDA: 18.9
21.9
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -194 446.1 N/A N/A
US
Abbvie Inc
NYSE:ABBV
14.4
12%
1.2
US
Amgen Inc
NASDAQ:AMGN
14.3
10%
1.4
US
Gilead Sciences Inc
NASDAQ:GILD
12.5
9%
1.4
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
21.2
18%
1.2
US
E
Epizyme Inc
F:EPE
Negative Multiple: -581 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
13.1
17%
0.8
NL
argenx SE
XBRU:ARGX
43
49%
0.9
AU
CSL Ltd
ASX:CSL
10.9
7%
1.6
US
S
Seagen Inc
F:SGT
Negative Multiple: -66.6 N/A N/A
P/E Multiple
Earnings Growth PEG
CN
Shanghai Haohai Biological Technology Co Ltd
SSE:688366
Average P/E: 35.5
35.2
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -160 127.7 N/A N/A
US
Abbvie Inc
NYSE:ABBV
86.7
97%
0.9
US
Amgen Inc
NASDAQ:AMGN
24.6
20%
1.2
US
Gilead Sciences Inc
NASDAQ:GILD
19.9
16%
1.2
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
28.3
19%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -533.6 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.7
14%
1.3
NL
argenx SE
XBRU:ARGX
39.6
30%
1.3
AU
CSL Ltd
ASX:CSL
32.4
9%
3.6
US
S
Seagen Inc
F:SGT
Negative Multiple: -61.8 N/A N/A

Market Distribution

In line with most companies in China
Percentile
41th
Based on 5 409 companies
41th percentile
21.9
Low
0 — 16.3
Typical Range
16.3 — 53.1
High
53.1 —
Distribution Statistics
China
Min 0
30th Percentile 16.3
Median 28.8
70th Percentile 53.1
Max 49 021

Shanghai Haohai Biological Technology Co Ltd
Glance View

Market Cap
9B CNY
Industry
Biotechnology

Shanghai Haohai Biological Technology Co., Ltd. operates at the cutting edge of the biopharmaceutical industry, specializing in regenerative medicine, medical aesthetics, and other biotechnology applications. Founded on the principles of innovation and science-driven solutions, the company has built an impressive portfolio that underscores its expertise in biological materials. Core to its operations is the development and commercialization of hyaluronic acid products, pivotal in fields such as ophthalmology, wound care, and more recently, dermal fillers for aesthetic treatments. Haohai Biological leverages high-end biotechnological processes to produce its offerings, ensuring that they meet the highest standards of quality and efficacy—a strategy that has allowed it to capture significant market share both domestically within China and beyond its borders. The revenue streams of Haohai Biological are as diversified as its product lines. The company generates income primarily through the sale of its high-margin pharmaceutical and medical device products. It has strategically positioned itself in the burgeoning market for medical aesthetics, where demand for cosmetic enhancements is rapidly growing, fueled by a global shift toward non-invasive procedures. Additionally, its ophthalmic products, crucial for surgeries and various ocular conditions, continue to be significant revenue drivers. Beyond product sales, Haohai invests in licensing its technologies and forging strategic partnerships with international firms, further enhancing its market reach and capitalizing on global biotechnology trends. This multifaceted approach positions the company not only as a producer but as a leader in scientific innovation and commercialization in the biotechnology sector.

Intrinsic Value
55.24 CNY
Undervaluation 29%
Intrinsic Value
Price ¥39.1
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett